BCAXBicara Therapeutics Inc.
$17.50+68% 1Y
$17.50
$10.5052 weeks$28.86
BCAX as reported
- Net income
- −$185M
Net income · +81% year on year · trailing twelve months to Q2 2026
- Free cash flow
- −$135M
Free cash flow · +34% year on year · trailing twelve months to Q2 2026
- EPS
- −$3.10
EPS · −170% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net income | −$185M | +81% | Q2 2026 |
| EPS | −$3.10 | −170% | Q2 2026 |
| ROE | −34% | n/a | Q2 2026 |
| ROA | −31% | n/a | Q2 2026 |
| Free cash flow | −$135M | +34% | Q2 2026 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Bicara Therapeutics Inc. (BCAX) · Net incomeNet incomeBicara Therapeutics Inc. (BCAX)
On our screens:Most shorted stocks
Biotechnology
The closest names by size in the same industry